-
1
-
-
84925286756
-
Melphalan and dexamethasone with or without bortezomib in newly-diagnosed AL amyloidosis: A matched case control study on 174 patients
-
Palladini G, Milani P, Foli A, Rosin MV, Basset M, Lavatelli F et al. Melphalan and dexamethasone with or without bortezomib in newly-diagnosed AL amyloidosis: a matched case control study on 174 patients. Leukemia 2014; 28: 2311-2316.
-
(2014)
Leukemia
, vol.28
, pp. 2311-2316
-
-
Palladini, G.1
Milani, P.2
Foli, A.3
Rosin, M.V.4
Basset, M.5
Lavatelli, F.6
-
2
-
-
84925286648
-
A matched comparison of cyclophophamide, bortezomib and dexamethasone (CVD) versus risk adapted cyclophosphamide, thalidomide, and dexamethasone (CTD) in AL amyloidosis
-
Venner CP, Gillmore JD, Sachchithanantham S, Mahmood S, Lane T, Forard D et al. A matched comparison of cyclophophamide, bortezomib and dexamethasone (CVD) versus risk adapted cyclophosphamide, thalidomide, and dexamethasone (CTD) in AL amyloidosis. Leukemia 2014; 28: 2304-2310
-
(2014)
Leukemia
, vol.28
, pp. 2304-2310
-
-
Venner, C.P.1
Gillmore, J.D.2
Sachchithanantham, S.3
Mahmood, S.4
Lane, T.5
Forard, D.6
-
3
-
-
84896718067
-
High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis
-
Dispenzieri A, Gertz MA, Kumar SK, Lacy MQ, Kyle RA, Saenger AK et al. High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis. Heart 2014; 100: 383-388.
-
(2014)
Heart
, vol.100
, pp. 383-388
-
-
Dispenzieri, A.1
Gertz, M.A.2
Kumar, S.K.3
Lacy, M.Q.4
Kyle, R.A.5
Saenger, A.K.6
-
4
-
-
4444268210
-
Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation
-
Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004; 104: 1881-1887.
-
(2004)
Blood
, vol.104
, pp. 1881-1887
-
-
Dispenzieri, A.1
Gertz, M.A.2
Kyle, R.A.3
Lacy, M.Q.4
Burritt, M.F.5
Therneau, T.M.6
-
5
-
-
84879458198
-
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis
-
Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 2013; 121: 3420-3427.
-
(2013)
Blood
, vol.121
, pp. 3420-3427
-
-
Wechalekar, A.D.1
Schonland, S.O.2
Kastritis, E.3
Gillmore, J.D.4
Dimopoulos, M.A.5
Lane, T.6
-
6
-
-
84856089226
-
Use of melphalan (M)/dexamethasone (D)/bortezomib in AL amyloidosis
-
Gasparetto C, Sanchorawala V, Snyder RM, Matous J, Terebelo HR, Janakiraman N et al. Use of melphalan (M)/dexamethasone (D)/bortezomib in AL amyloidosis. J Clin Oncol 2010; 28(15 Suppl): 8024.
-
(2010)
J Clin Oncol
, vol.28
, Issue.15
, pp. 8024
-
-
Gasparetto, C.1
Sanchorawala, V.2
Snyder, R.M.3
Matous, J.4
Terebelo, H.R.5
Janakiraman, N.6
-
7
-
-
84860898706
-
Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis
-
Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 2012; 119: 4391-4394.
-
(2012)
Blood
, vol.119
, pp. 4391-4394
-
-
Mikhael, J.R.1
Schuster, S.R.2
Jimenez-Zepeda, V.H.3
Bello, N.4
Spong, J.5
Reeder, C.B.6
-
8
-
-
84860897399
-
Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival
-
Venner CP, Lane T, Foard D, Rannigan L, Gibbs SD, Pinney JH et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 2012; 119: 4387-4390.
-
(2012)
Blood
, vol.119
, pp. 4387-4390
-
-
Venner, C.P.1
Lane, T.2
Foard, D.3
Rannigan, L.4
Gibbs, S.D.5
Pinney, J.H.6
-
9
-
-
79960934028
-
Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: Results of a phase 1/2 study
-
Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Blade J et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood 2011; 118: 865-873.
-
(2011)
Blood
, vol.118
, pp. 865-873
-
-
Reece, D.E.1
Hegenbart, U.2
Sanchorawala, V.3
Merlini, G.4
Palladini, G.5
Blade, J.6
-
10
-
-
70349575412
-
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: Results of a phase 1 dose-escalation study
-
Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand JP et al. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood 2009; 114: 1489-1497.
-
(2009)
Blood
, vol.114
, pp. 1489-1497
-
-
Reece, D.E.1
Sanchorawala, V.2
Hegenbart, U.3
Merlini, G.4
Palladini, G.5
Fermand, J.P.6
|